“A study, from 1843, suggested that cannabis sativa ‘possess very striking powers as an antispasmodic, as a nervine stimulant, and as an anodyne and hypnotic, and in some respects to excel opium in virtue.'”
Approximately 60 patients suffering breakthrough cancer pain to participate in clinical trial that compares fentanyl with inhaled medical cannabis.
A cannabis-derived drug that could reduce opioid fentanyl use for breakthrough cancer pain is one step closer thanks to Health Canada approval that will allow a clinical trial to begin in October.
People who use cannabis for chronic, non-cancer pain are not likely to find significant relief and may even experience more severe pain over time, according to a four-year study conducted by the prestigious medical journal The Lancet.